Capricor Therapeutics (CAPR) Profit After Tax (2010 - 2026)

Capricor Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at -$34.5 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 46.19% year-over-year to -$34.5 million in Q1 2026; TTM through Mar 2026 was -$116.4 million, a 118.29% decrease from a year earlier, with the FY2025 full-year figure at -$105.8 million, down 166.63% from the prior year.
• Profit After Tax eased to -$34.5 million in Q1 2026 per CAPR's latest filing, from -$30.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$770053.0 in Q4 2023 and bottomed at -$34.5 million in Q1 2026.
• The 5-year median for Profit After Tax is -$7.8 million (2022), against an average of -$13.6 million.
• Across the five-year window, Profit After Tax soared 90.02% in 2023 and sank 703.3% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$7.7 million in 2022, then soared by 90.02% to -$770053.0 in 2023, then plunged by 703.3% to -$6.2 million in 2024, then slumped by 399.76% to -$30.9 million in 2025, then dropped by 11.6% to -$34.5 million in 2026.
• Per Business Quant, the three latest CAPR Profit After Tax figures stand at -$34.5 million (Q1 2026), -$30.9 million (Q4 2025), and -$25.1 million (Q3 2025).